Testing revumenib for relapsed acute leukemia with certain gene changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active acute leukemia (cancer growing in the blood or bone marrow) or leukemia with KMT2A, NUP98, or NPM1 gene changes
- Your bone marrow has enough leukemia cells (bone marrow blasts at least 5%) or leukemia has returned in peripheral blood
- Your white blood cell count is below 25,000 at enrollment (you may be allowed to reduce it beforehand)
- You are able to take part physically (ECOG 0–2 or good functional status score ≥50)
- Prior treatments side effects have mostly improved (generally back to Grade 1, except limited Grade 2 neuropathy or hair loss)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
This trial tests a combination of three drugs (revumenib, azacitidine, and venetoclax) for children and young adults with a hard-to-treat type of leukemia that has a specific genetic change. The goal is to see if this new mix can help when standard treatments have not worked.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial tests two new drug combinations for a specific type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) that has a genetic change called KMT2A-rearrangement. The goal is to help patients who are at higher risk of their cancer coming back after initial treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.